RecruitingNot ApplicableNCT06815354

Comprehensive Assessment of Cancer Theranostic Response

Comprehensive Assessment of Cancer Theranostic Response; Investigating the Intent to Change Treatment Decisions Based on TRAQinform Theranostics

Sponsor

AIQ Solutions

Enrollment

32 participants

Start Date

Dec 2, 2024

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer

Summary

The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at the best ways to track how well cancer treatments are working in people with metastatic prostate cancer — cancer that has spread beyond the prostate. Researchers are comparing different imaging tools and blood-based tests (called biomarkers) to find the most accurate combination for measuring treatment response, which could help doctors adjust therapies more effectively. **You may be eligible if...** - You are 18 or older - You have been diagnosed with metastatic prostate cancer - You are scheduled to start or continue treatment **You may NOT be eligible if...** - You have a serious current disease, infection, or other condition that would interfere with study participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETRAQinform Theranostics

This prospective, multi-center, non-interventional clinical study will evaluate actionable outputs from TRAQinform Theranostics, a software only medical device that identifies, quantifies, tracks, and compares lesions between different imaging modalities and multiple imaging timepoints.

Locations(2)

Weill Medical College of Cornell

New York, New York, United States

M.D. Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06815354

Related Trials

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT0733644618 locations

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT0700515433 locations

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT068073593 locations

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT046926751 location

DESTINY-PANTUMOUR04

NCT0712400017 locations